List of Excipients in Branded Drug METRONIDAZOLE250 MG

« Back to Dashboard

Generic Drugs Containing METRONIDAZOLE250 MG

Company	Ingredient	NDC	Excipient
Cambridge Therapeutics Technologies LLC	metronidazole	70882-130	ANHYDROUS LACTOSE
Cambridge Therapeutics Technologies LLC	metronidazole	70882-130	CELLULOSE, MICROCRYSTALLINE
Cambridge Therapeutics Technologies LLC	metronidazole	70882-130	DIACETYLATED MONOGLYCERIDES

What are the Most Frequently-Used Excipients in METRONIDAZOLE250 MG?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	DIACETYLATED MONOGLYCERIDES

Metronidazole 250 mg Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Metronidazole 250 mg is a mature, multisource generic product with limited active-ingredient patent risk and substantial price competition. Commercial opportunity is concentrated in formulation differentiation, supply reliability, pediatric and geriatric usability, taste masking, preservative systems, and geographic markets where oral solid-dose access remains uneven. The strongest near-term platform is a robust immediate-release 250 mg tablet, supported by an oral suspension or dispersible presentation for patients who cannot swallow tablets.

What is the regulatory and commercial status of metronidazole 250 mg?

Metronidazole is a synthetic nitroimidazole antimicrobial marketed in the United States and globally for anaerobic bacterial infections and selected protozoal infections. The 250 mg strength is generally supplied as an immediate-release oral tablet, although metronidazole is also available in other strengths, dosage forms, and routes.

Attribute	Assessment
Active ingredient	Metronidazole
Common oral strength	250 mg
Primary oral dosage form	Immediate-release tablet
Regulatory pathway	Abbreviated New Drug Application, or ANDA, for generic products
Reference product	Flagyl tablets and historical branded equivalents
Typical use	Anaerobic infections, trichomoniasis, giardiasis, amebiasis and related labeled indications
Biosimilar exposure	None; metronidazole is a synthetic small molecule
Current U.S. patent risk	Low for the active ingredient and basic 250 mg tablet
Main commercial risk	Price erosion, substitution, manufacturing interruptions and procurement concentration
Main product opportunity	Patient-centered formulation and reliable low-cost supply

FDA-approved metronidazole tablets are available from multiple generic manufacturers. FDA labeling for oral metronidazole identifies the product as an immediate-release dosage form and provides dosing regimens that use 250 mg, 375 mg and 500 mg tablets depending on the indication and patient population. FDA-listed products and labels should be checked before launch because inactive ingredients, tablet appearance, scoring and package configurations vary by manufacturer. [1,2]

What excipients are used in metronidazole 250 mg tablets?

Metronidazole 250 mg tablets typically use conventional direct-compression or wet-granulation excipients. Exact compositions are product-specific and must be verified against the target reference product and current FDA Inactive Ingredient Database entries.

Common excipient classes include:

Excipient class	Typical examples	Function
Diluent	Microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate	Provides tablet mass and improves compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet cohesion
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup and dissolution
Lubricant	Magnesium stearate, stearic acid	Reduces ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film former	Hypromellose	Creates a protective and cosmetic film
Plasticizer	Polyethylene glycol, propylene glycol	Improves film flexibility
Opacifier or colorant	Titanium dioxide, iron oxides or approved colorants	Controls appearance and light protection
Sweetener or flavor	Sucralose, saccharin, fruit flavors	More relevant to liquid and chewable products

A typical 250 mg immediate-release tablet should prioritize fast disintegration, reproducible dissolution and low manufacturing cost. A simple excipient system can be commercially attractive because it reduces raw-material complexity and limits supply-chain exposure.

How should the tablet excipient system be designed?

A practical formulation strategy is:

1. Use microcrystalline cellulose or a comparable diluent for compactibility.
2. Select one primary disintegrant and optimize its intragranular and extragranular placement.
3. Keep magnesium stearate concentration and blending time tightly controlled because over-lubrication can slow dissolution.
4. Use a low-weight film coat when appearance, swallowability or moisture protection is required.
5. Avoid unnecessary excipient diversity unless it solves a demonstrated manufacturing or patient-use problem.

Metronidazole has a strong, bitter taste and a characteristic odor that can affect patient acceptance. Film coating can reduce direct exposure to the drug during swallowing, but it does not eliminate taste issues if the tablet is chewed, split or dispersed.

What are the best excipient strategies for metronidazole 250 mg?

The optimal strategy depends on the intended market and dosage form.

Standard low-cost generic tablet

The baseline product should use a conventional, broadly available excipient system with:

• Immediate-release dissolution
• Robust hardness and friability performance
• A score line if supported by dose-splitting data
• A light-colored, film-coated presentation
• Low hygroscopicity
• Broad supplier availability
• Compatibility with high-speed compression

This approach is appropriate for hospital tenders, government procurement and retail generic substitution. It offers the lowest development and manufacturing risk but limited differentiation.

Taste-masked tablet

Taste masking is commercially relevant when the tablet is likely to be crushed, dispersed or administered to children. Options include:

• Polymer film coating
• Ion-exchange resin complexes
• Lipid or wax-based barriers
• Multiparticulate coating
• Effervescent or flavored dispersion systems

A heavily coated tablet can create dissolution risk if the film is too dense or poorly permeable. A resin-complex approach can improve taste control but adds process steps, analytical work and scale-up risk.

Pediatric oral suspension

A 250 mg dose can be delivered through a lower-strength suspension, but an oral liquid is not equivalent to a 250 mg tablet from a formulation perspective. It must address:

• Sedimentation and redispersibility
• Palatability
• Preservative efficacy
• Microbial control
• Container compatibility
• Dose-measuring accuracy
• Stability after reconstitution, if supplied as a powder

Potential excipient systems include suspending agents such as xanthan gum, sodium carboxymethylcellulose or microcrystalline cellulose-sodium carboxymethylcellulose; sweeteners such as sucrose or sorbitol; flavors; buffers; and preservatives where permitted and justified.

The best commercial formulation may be a ready-to-use suspension for institutional use or a powder for reconstitution for markets with difficult cold-chain and distribution conditions. A powder can reduce shipping weight and improve microbiological stability before reconstitution.

Dispersible or orally disintegrating tablet

A dispersible 250 mg tablet could address swallowing difficulty and pediatric administration. The principal formulation constraints are:

• Fast dispersion in a small volume of water
• Low residual bitterness
• Adequate mechanical strength
• Limited friability
• Dose uniformity
• Packaging protection from humidity

This product can be differentiated from standard generic tablets, but it requires more extensive palatability and administration studies. It is most attractive where pediatric or geriatric demand is visible and procurement systems recognize the added value.

What formulation patents protect metronidazole 250 mg?

The original active-ingredient and branded-product patent position for metronidazole is historic rather than commercially relevant to a new conventional generic launch. Metronidazole has been marketed for decades, and standard 250 mg tablets are supplied by multiple generic manufacturers.

The relevant IP risks today are more likely to arise from:

• A proprietary taste-masking process
• A novel controlled-release matrix
• A specific suspension system
• A delivery device
• A combination product
• A newly claimed method of use
• Manufacturing know-how that is not publicly disclosed as a patent

A formulation patent would need to claim a genuine technical distinction, such as a defined dissolution profile, stability advantage, taste-masking architecture or process limitation. A conventional tablet containing metronidazole, a diluent, a disintegrant and magnesium stearate is unlikely to provide meaningful exclusivity by itself.

Patent clearance must be performed separately for the intended jurisdiction, indication and dosage form. The absence of meaningful U.S. active-ingredient risk does not establish freedom to operate in every foreign market.

What is the Orange Book status of metronidazole 250 mg?

Metronidazole tablets are generic products approved through the ANDA pathway and listed in FDA drug databases. The Orange Book identifies approved products, reference-listed drugs, therapeutic-equivalence codes and patent or exclusivity information where applicable. [3]

For a conventional metronidazole 250 mg tablet:

• There is no current branded-market exclusivity comparable to a newly approved drug.
• Biosimilar analysis does not apply.
• Paragraph IV litigation is not the primary market issue.
• Generic approval depends on pharmaceutical equivalence, bioequivalence, manufacturing quality and labeling conformity.
• Product-specific labeling and inactive ingredients must be checked for each ANDA holder.

A sponsor developing a new tablet should expect the principal regulatory burden to involve formulation development, analytical method validation, stability, bioequivalence strategy and current good manufacturing practice compliance rather than a first-filer patent contest.

When does metronidazole lose exclusivity?

Metronidazole’s original market exclusivity expired decades ago. The molecule is now a mature generic active ingredient. Commercial exclusivity may still arise temporarily from:

• A newly approved novel formulation
• A qualifying pediatric exclusivity award
• A new indication with applicable statutory protection
• A proprietary combination product
• A jurisdiction-specific regulatory award

Those possibilities do not create exclusivity for a standard 250 mg immediate-release tablet. Product developers should not assume that a new excipient combination creates regulatory exclusivity.

Are Paragraph IV challenges or patent litigation relevant?

Paragraph IV activity is unlikely to be a major barrier for a conventional metronidazole 250 mg tablet because the product has long been genericized. The relevant litigation risks are more likely to involve:

• Contract manufacturing disputes
• Product liability claims
• Labeling and failure-to-warn claims
• Quality failures and recalls
• Procurement disputes
• Trademark or packaging disputes
• Patent claims directed to a specific newer formulation

A later entrant may face aggressive price competition without facing significant patent litigation. That changes the investment profile: development risk is moderate, while commercialization and margin risk are high.

What commercial opportunities exist for metronidazole 250 mg?

Hospital and institutional procurement

Hospitals use metronidazole in oral and intravenous treatment pathways. A reliable 250 mg tablet can support step-down therapy after intravenous treatment. Commercial advantages include:

• Consistent supply
• Unit-dose packaging
• Barcode compatibility
• Clear tablet identification
• Competitive tender pricing
• Pack sizes aligned with inpatient and outpatient use

Procurement buyers may value supply reliability more than minor formulation differences.

Pediatric and swallowing-difficulty markets

A taste-masked suspension, dispersible tablet or smaller unit-dose presentation can command a more defensible position than a standard tablet. The opportunity is strongest where existing products have poor palatability, limited availability or inconsistent supply.

Emerging markets

Metronidazole remains important in markets with substantial anaerobic and protozoal disease burden. Opportunities may exist in:

• Low-cost tablets
• Heat- and humidity-tolerant packaging
• Powder-for-reconstitution products
• Government tenders
• Local manufacturing partnerships
• Regional products using pharmacopeial excipients

Packaging should be selected for climatic conditions. High-barrier blister systems, desiccant-supported bottles and moisture-resistant film coats may reduce stability failures in hot and humid regions.

Contract manufacturing and private-label supply

Because the molecule and tablet technology are mature, a manufacturer with validated processes can offer private-label supply to hospitals, distributors and regional pharmaceutical companies. The strongest differentiators are quality consistency, registration support, short lead times and multi-country documentation.

How does metronidazole compare with other generic antibiotics?

Product	Patent risk	Formulation differentiation	Price pressure	Main opportunity
Metronidazole 250 mg	Low	Moderate through taste masking and liquids	High	Reliable supply and patient-centered dosage forms
Amoxicillin 250 mg	Low	Moderate, especially suspensions	High	Pediatric products and combination packs
Clindamycin 150 mg	Low to moderate	Moderate	Moderate to high	Capsule reliability and tolerability positioning
Tinidazole 500 mg	Low	Moderate	Moderate	Longer dosing and selected protozoal indications
Oral vancomycin	Product-specific	High	Lower volume, higher value	Specialty formulations and compounding alternatives

Metronidazole has greater formulation flexibility than many basic oral antibiotics because it can be developed as tablets, capsules, suspensions, vaginal products, topical gels and injectable products. That flexibility does not remove price pressure in the standard tablet segment.

What manufacturing and intellectual-property barriers matter?

The manufacturing barriers are operational rather than molecule-specific:

• Control of tablet weight and content uniformity
• Dissolution consistency across batches
• Odor and dust management
• Moisture control
• Film-coating uniformity
• Suspension redispersibility
• Preservative efficacy
• Container-closure compatibility
• Stability under climatic zone conditions

For an oral liquid, microbiological robustness and palatability can become the main development risks. For a tablet, compression behavior, coating performance and dissolution are more important.

The most defensible technical position is usually a documented process advantage rather than a broad composition claim. Examples include a low-dust granulation process, improved stability under high humidity, a validated taste-masking system or a suspension with superior redispersibility.

What is the recommended product-development strategy?

A staged portfolio is commercially stronger than a single undifferentiated tablet.

Stage	Product	Strategic purpose
1	Immediate-release 250 mg film-coated tablet	Establish regulatory approval and base-volume access
2	250 mg or equivalent pediatric suspension	Address palatability and swallowing barriers
3	Dispersible or orally disintegrating product	Create differentiated patient-use positioning
4	Regional private-label and institutional packs	Expand tender and distributor channels
5	Selected topical, vaginal or combination products	Use platform capabilities for adjacent markets

The base tablet should avoid unnecessary formulation novelty. Differentiation should be reserved for products where the excipient system solves a clear problem and supports a credible commercial premium.

Key Takeaways

• Metronidazole 250 mg is a mature generic product with low active-ingredient patent risk.
• The standard immediate-release tablet is technically straightforward but highly exposed to price competition.
• The most useful excipient priorities are rapid dissolution, robust manufacturability, moisture control and taste reduction.
• Pediatric suspension and dispersible formulations offer greater differentiation than a conventional tablet.
• Orange Book and ANDA considerations focus on product approval, therapeutic equivalence and current labeling rather than pioneer-drug exclusivity.
• Paragraph IV and biosimilar risks are limited for a standard 250 mg product.
• Commercial value is most likely to come from supply reliability, institutional packaging, regional registration support and patient-centered dosage forms.
• Any formulation patent strategy must rely on a defined technical improvement rather than routine excipient substitution.

FAQs About Metronidazole 250 mg Excipient and Commercial Strategy

Can metronidazole 250 mg tablets be made without lactose?

Yes. Lactose-free formulations can use microcrystalline cellulose, dibasic calcium phosphate, mannitol or other suitable diluents. The substitution must be evaluated for compression, dissolution, stability and bioequivalence.

Which excipients are most important for metronidazole taste masking?

Film-coating polymers, ion-exchange resins, lipid barriers and flavor systems are the main options. The selected system must be evaluated for dissolution and dose release, not only sensory performance.

Is a metronidazole 250 mg suspension more commercially attractive than a tablet?

It can be, particularly for pediatric, geriatric and swallowing-difficulty populations. The suspension has higher formulation and microbiological complexity but offers more differentiation than a conventional tablet.

Does metronidazole 250 mg require a biosimilar development program?

No. Metronidazole is a synthetic small-molecule drug. A generic product normally follows the applicable ANDA or equivalent national generic pathway.

Can a new excipient combination create patent protection for metronidazole?

Only if the formulation produces a patentable technical result and satisfies novelty, inventive-step or non-obviousness and disclosure requirements in the relevant jurisdiction. Routine substitution of common tablet excipients is unlikely to provide strong protection.

References

1. U.S. Food and Drug Administration. (2023). Flagyl (metronidazole) tablets, prescribing information. FDA.
2. DailyMed. (2024). Metronidazole tablet: drug labeling and inactive ingredients. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
5. United States Pharmacopeia. (2024). Metronidazole monograph and general chapters. United States Pharmacopeial Convention.